{"id":13273,"date":"2020-12-23T00:00:00","date_gmt":"2020-12-23T00:00:00","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/absolute-antibody-offers-researchers-sars-cov-2-neutralizing-antibodies-derived-from-covid-19-patients\/"},"modified":"2020-12-23T00:00:00","modified_gmt":"2020-12-23T00:00:00","slug":"absolute-antibody-offers-researchers-sars-cov-2-neutralizing-antibodies-derived-from-covid-19-patients","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/absolute-antibody-offers-researchers-sars-cov-2-neutralizing-antibodies-derived-from-covid-19-patients\/","title":{"rendered":"Absolute Antibody offers researchers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients"},"content":{"rendered":"<p>Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody\u2019s online catalogue.<br \/>\nThe new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a <link https:\/\/covid19.elsevierpure.com\/en\/publications\/analysis-of-a-sars-cov-2-infected-individual-reveals-development _blank>recent study<\/link> to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.<br \/>\nAbsolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.<br \/>\nThe new neutralizing antibodies join Absolute Antibody\u2019s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.<br \/>\nAbsolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.<\/p>\n<ul>\n<li>For more information, visit: <link https:\/\/absoluteantibody.com\/general\/sars-cov-2-neutralizing-antibodies _blank>https:\/\/absoluteantibody.com\/general\/sars-cov-2-neutralizing-antibodies<\/link><\/li>\n<\/ul>\n<p><!--more--><br \/>\n<strong>Supplier:<\/strong> [No title]<br \/>\n<strong>Website:<\/strong> <a href=\"https:\/\/absoluteantibody.com\/general\/sars-cov-2-neutralizing-antibodies\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/absoluteantibody.com\/general\/sars-cov-2-neutralizing-antibodies<\/a><\/p>\n<p><a class=\"avia-button avia-color-theme-color\" href=\"mailto:info@absoluteantibody.com\">Mail the supplier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":13202,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/13273"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=13273"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/13273\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/13202"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=13273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=13273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=13273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}